Your session is about to expire
← Back to Search
Deferoxamine for Subarachnoid Hemorrhage (DISH Trial)
DISH Trial Summary
This trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment of aSAH.
DISH Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDISH Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DISH Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with a brain aneurysm using special imaging tests.I have a significant disability, with difficulty in daily activities.I have a serious lung condition or need home oxygen.I have severe anemia or need blood transfusions often.I have severe hearing loss.You have low levels of blood cells (platelets or neutrophils).I have a blood clotting disorder or I'm taking medication to prevent blood clots.I am taking iron supplements with more than 325 mg of ferrous iron.You need to have a Glasgow Coma Scale score of 7 or higher after having an External Ventricular Drain placed if it is needed.You have other health problems that may significantly shorten your life.I was independent in daily activities before my stroke.My brain hemorrhage is classified between Grade I and IV.My aneurysm was treated with a procedure inside the vessel or surgery.I have had liver problems in the past.You have a Hunt-Hess score of 4 or lower.You must be able to take the first dose of the drug within 24 hours of feeling symptoms.Your brainstem function cannot be fixed.My kidney function is not normal, with a creatinine level over 2 mg/dL.You had an allergic reaction to deferoxamine before, or you were treated with it before.You have a very large aneurysm, bigger than 25 millimeters.
- Group 1: Placebo
- Group 2: Deferoxamine lower dose
- Group 3: Deferoxamine higher dose
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this clinical trial accept individuals aged 45 and above?
"According to the requirements of this trial, eligible patients must be at least 18 years old and not exceed 80 years in age."
Do I meet the criteria to be part of this research endeavor?
"This clinical trial is open to 120 individuals with a history of haemorrhaging between 18 and 80 years old. To be considered, the patient must meet specific criteria such as having undergone endovascular or microsurgical treatment for their aneurysm, being under Hunt-Hess Grade 4 after EVD placement if applicable, and achieving a GCS score above 7 following drug administration within 24 hours of symptom onset. Additionally, applicants need to have been functionally independent before SAH occured and achieved mRS ≤ 1 at the time of informed consent from either themselves or their legal authorised representative."
What is the magnitude of enrollees in this clinical trial?
"Yes, according to the clinicaltrials.gov website, this clinical trial is currently enlisting volunteers. It was first published on March 20th 2022 and last modified on March 28th 2022; it requires 120 individuals from a single medical site."
What potential adverse effects can be associated with Deferoxamine treatment?
"Our team at Power has rated the safety of Deferoxamine a 2 due to it being in Phase 2 trials, implying that there are preliminary findings which support its security but not much on its efficacy."
Could you please detail any other research investigations that have utilized Deferoxamine?
"Currently, a total of 5 studies are researching Deferoxamine; none of these investigations is at the Phase 3 stage. Most locations for this trial are in Boston, Massachusetts but there are 7 other sites across the country running trials as well."
What medical conditions is Deferoxamine typically used to treat?
"Deferoxamine is a viable therapeutic option to address iron overload, aluminum accumulation and chronic aluminium poisoning."
Is acceptance of new participants still happening for this investigation?
"According to the clinicaltrials.gov website, this medical experiment is currently searching for participants and was initially made available on March 20th 2022 with a recent update posted on March 28th of that year."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger